Clay B. Siegall - 13 Dec 2023 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Director
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
13 Dec 2023
Net transactions value
$0
Form type
4
Filing time
15 Dec 2023, 16:23:26 UTC
Previous filing
04 Oct 2023
Next filing
08 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Stock Option (Right to Buy) Award $0 +20,000 $0.000000 20,000 13 Dec 2023 Common Stock 20,000 $18.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest and become exercisable in thirty-six (36) equal monthly installments beginning on January 13, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.